Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Rhea-AI Summary
Xilio Therapeutics (Nasdaq: XLO) said company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 3:00 p.m. ET.
A live webcast will be available at the company investor site ir.xiliotx.com, with a replay archived for 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – XLO
In the Mar 2 session, XLO gained 2.37%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.3% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Financing announcement | Positive | +11.4% | Underwritten offering of pre-funded warrants raising about $40M gross proceeds. |
| Jan 08 | Corporate update | Positive | +2.6% | Cash runway into Q2 2027 and program milestones plus board leadership change. |
| Nov 13 | Earnings & pipeline | Positive | -9.3% | Q3 2025 results with positive vilastobart and XTX501 updates and solid cash. |
| Nov 07 | Phase 2 data | Positive | -3.0% | Late-breaking Phase 2 vilastobart data showing 40% ORR in selected MSS mCRC. |
| Nov 07 | Clinical portfolio | Positive | -3.0% | SITC 2025 showcase of masked immunotherapy platform and early clinical results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent financings and clinical updates were mostly positive but produced mixed reactions: two financing/corporate updates saw gains, while three clinical/earnings updates with favorable data coincided with share price declines.
Over the past several months, Xilio has combined financing, pipeline progress, and corporate actions. On Feb 11, 2026, it priced pre-funded warrants for roughly $40.0M, which was followed by an 11.44% gain. A Jan 8, 2026 update highlighted $137.5M in cash and extended runway into Q2 2027. In late 2025, strong Phase 2 vilastobart data and broader SITC presentations coincided with modest declines, as did Q3 2025 financial results, showing that positive clinical news did not always translate into immediate price strength. Today’s conference participation fits this ongoing communication cadence.
Key Terms
immuno-oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor Contact
Alex Lobo, Precision AQ
alex.lobo@precisionaq.com
Media Contact
Josie Butler, 1AB
josie@1abmedia.com
